The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Genome Editing Services Market-Focus on CRISPR 2019-2030

  • Lowest Price Guaranteed From USD 4,499

  • Published
    October 2019

  • Pages
    290

  • View Count
    3587

Example Insights

Genome Editing Services Market Focus on CRISPR, 2019-2030-Context Genome Editing Services Market Focus on CRISPR, 2019-2030-List of CRISPR based Genome Editing Services Market Focus on CRISPR, 2019-2030-Distribution by company size
Genome Editing Services Market Focus on CRISPR, 2019-2030-Grant Analysis Genome Editing Services Market Focus on CRISPR, 2019-2030-CRISPR based technology developers Genome Editing Services Market Focus on CRISPR, 2019-2030-Patnerships and collaborations
Genome Editing Services Market Focus on CRISPR, 2019-2030-Market Forecast Genome Editing Services Market Focus on CRISPR, 2019-2030-Patent Analysis  

 

Overview

The 1970s witnessed the introduction of one of the most revolutionary advances in biotechnology, when Hamilton Smith (a molecular biologist at Johns Hopkins University School of Medicine) purified the first site-specific restriction enzyme, called Hind II. This development enabled the scientific community to devise the means to manipulate living organisms at the genetic level, opening up a plethora of opportunities in fundamental and applied life science research. Soon after, in the 1980s, the US FDA approved the world’s first genetically engineered drug, which was human insulin marketed under the brand name HUMULIN®. Genetic engineering and genome editing concepts have evolved significantly over the last two decades, with the development of a variety of versatile DNA modulation technologies including zinc finger nucleases, transcription activator-like effector-based nucleases (TALENs), and the clustered regularly interspaced short palindromic repeats (CRISPR). These developments have enabled medical researchers to perform an array of gene / cell line engineering experiments, including gene knockdowns, gene overexpressions and single base editing, for a variety of R&D applications. It is worth highlighting that, of all the available genome manipulation technologies, CRISPR is currently considered to be the most popular tool, owing to its fast, accurate, and cost-effective approach. In fact, in 2018, scientists Emmanuelle Charpentier, Jennifer Doudna, and Virginijus Siksnys were felicitated for their pioneering efforts on the CRISPR-Cas9 technology, with the prestigious Kavli Prize in Nanoscience.  

Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques. The biopharmaceutical pipeline includes close to 500 gene therapies, several of which are being developed based on the CRISPR technology. Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based therapy was initiated. However, successful gene manipulation efforts involve complex experimental protocols and advanced molecular biology centered infrastructure. Therefore, many biopharmaceutical researchers and developers have demonstrated a preference to outsource such operations to capable contract service providers. Consequently, the genome editing contract services market was established and has grown to become an indispensable segment of the modern healthcare industry, offering a range of services, such as gRNA design and construction, cell line development (involving gene knockout, gene knockin, tagging and others) and transgenic animal model generation (such as knockout mice). Additionally, there are several players focused on developing advanced technology platforms that are intended to improve / augment existing gene editing tools, especially the CRISPR-based genome editing processes. Given the rising interest in personalized medicine, a number of strategic investors are presently willing to back genetic engineering focused initiatives. Prevalent trends indicate that the market for CRISPR-based genome editing services is likely to grow at a significant pace in the foreseen future.

The “Genome Editing Services Market: Focus on CRISPR, 2019-2030” report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographical regions. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape, featuring an elaborate list of over 80 companies that offer CRISPR-based genome editing services, and analyses based on a number of relevant parameters, such as type of gRNA service, availability of gRNA format, type of endonuclease, type of Cas9 endonuclease format, type of cell line engineering offering, type of cell line, type of animal model generation offering, availability of CRISPR libraries and important service provider details (year of establishment, company size and location of headquarters).  
  • An insightful 2X2 representation, highlighting the competitiveness of various CRISPR-based genome editing service providers captured in our database (segregated across various peer groups based on company size), taking into consideration the supplier power and the specific genome editing capabilities (which include gRNA service(s), endonuclease service(s), cell line engineering service(s), animal model generation service(s) and availability of CRISPR library(s)) of different companies.
  • Elaborate profiles of key players (shortlisted based on strength of service portfolio), featuring a brief overview of the company, its financial performance (if available), a detailed description of its genome editing service offerings, recent developments and an informed future outlook.
  • An in-depth analysis of over 10,000 patents related to CRISPR technology that have been filed / granted, since 2006, highlighting key trends associated with these patents, across type of patent, publication year and application year, regional applicability, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent benhcmarking and valuation.  
  • A detailed analysis of close to 2,000 grants that have been awarded to support research projects related to CRISPR, between 2015 and 2019 (till September), highlighting important parameters, such as year of award, amount awarded, administring institute center, support period, funding mechanism, type of grant application, grant activity, type of recipient organization, regional distribution of recipient organization, prominent project leaders and emerging focus areas. It also features a detailed multivariate grant attractiveness analysis based on the amount awarded, support period, grant type and funding mechanism.
  • A discussion on the advanced technologies and systems that have been developed to improve CRISPR-related processes. It includes a list of companies that have developed such innovative technology platforms, along with details on a number of relevant parameters, such as year of establishment, company size, core expertise, location of headquarters and important technology specifications (including technology name, focus area and key features). In addition, it includes short profiles of key technology providers. Further, the chapter highlights a list of companies that offer CRISPR kits and CRISPR design tools.
  • An analysis highlighting potential strategic partners, segregated based on likelihood of entering into collaboration with CRISPR-based genome editing services providers. The analysis takes into consideration multiple relevant parameters, such as type of therapy, pipeline strength, pipeline maturity, company strength and therapeutic area.
  • A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall market.

One of the key objectives of the report was to evaluate the current opportunity and the future potential of CRISPR-based genome editing services market. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030. In addition, we have segmented the future opportunity across [A] type of services offered (gRNA construction, cell line engineering and animal model generation), [B] type of cell line used (mammalian, microbial, insect and others) and [C] different geographical regions (North America, Europe, Asia Pacific and rest of the world). To account for the uncertainties associated with the CRISPR-based genome editing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

    
The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the CRISPR-based genome editing services market in the short to mid-term, and long term.

Chapter 3 provides a brief overview, history and applications of genome editing. It includes detailed discussion on the different types of currently available genome editing techniques. In addition, the chapter provides details of CRISPR technology along with the information on role of CRISPR / Cas in bacterial adaptive immunity, key CRISPR / Cas systems and components of CRISPR / Cas system. Further, it includes details on protocol associated with CRISPR-based genome editing, applications of CRISPR and associated key challenges and future perspectives.

Chapter 4 provides a comprehensive view on the current landscape of CRISPR-based genome editing service providers. It includes information related to over 80 companies that claim to offer CRISPR-based genome editing services, featuring an in-depth analyses of the players based on their service offering including gRNA service (gRNA design and gRNA construction), availability of gRNA format (plasmid, lentivirus, AAV, adenovirus and others), type of endonuclease (Cas9, Cpf1 and others), availability of Cas9 format (mRNA, plasmid, lentivirus, AAV, protein and others), type of cell line engineering offering (knockout, knockin, tagging / reporters and others), type of cell line (stem cell lines, human cell lines, other mammalian cell lines and others (microbial, insects and others)), type of animal model generation offering (mice / mouse, rat, zebrafish, C.elegans and others), availability of CRISPR libraries and important service provider details (year of establishment, headquarter location(s), company size).

Chapter 5 features a comprehensive 2X2 analysis offering a comparative summary of all the CRISPR-based genome editing service providers that we came across during our research. The analysis compares the aforementioned companies within three peer-groups, established based on size of employee base (small-sized (1-200 employees), mid-sized (>201-1,000 employees) and large (>1,000 employees)). The companies were compared based on their genome editing capabilities (including gRNA service(s), endonuclease service(s), cell line service(s), animal model generation service(s), CRISPR library(s)) and supplier power.

Chapter 6 features profiles of CRISPR-based genome editing service providers (shortlisted based on strength of service portfolio). Each profile features an overview of the company, its financial performance (if available), brief details of genome editing service portfolio, recent developments and an informed future outlook.

Chapter 7 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed since 2006 related to CRISPR technology. The analysis also highlights the key trends associated with these patents, including type of patent (granted patent, patent application and others), publication year and application year, geography (North America, Europe, Asia-Pacific and Rest of the World), CPC symbols (Top 15 CPC symbols), key focus areas, leading industry / non-industry players, patent benchmarking analysis and patent valuation analysis.

Chapter 8 provides information on close to 2,200 grants that were awarded to research institutes engaged in projects related to CRISPR technology, between 2015 and 2019 (till September). The analysis also highlights important parameters associated with grants, such as year of award, amount awarded, administering institute center, support period, funding mechanism, type of grant application, grant activity, type of recipient organization, regional distribution of recipient organization, prominent project leaders and emerging focus areas. It also features a detailed multivariate grant attractiveness analysis based on the amount awarded, support period, grant type and funding mechanism.

Chapter 9 provides details of innovative technology platforms (such as integration of delivery platforms, enzyme technologies, protein technologies and others with the fundamental CRISPR technology) to improve CRISPR processes. It includes the list of companies that are focused on the development of these technologies along with details on a number of parameters, such as year of establishment, headquarter location(s), company size, company expertise and technology details (name, focus and key features). In addition, it includes tabulated profiles of key technology providers, with details on company overview, funding and collaboration instances. Further, the chapter highlights a list of companies that offer CRISPR design tools and kits.

Chapter 10 features an insightful analysis, highlighting potential strategic partners (for instance, drug developers) for CRISPR-based genome editing service providers, based on multiple parameters, such as type of therapy, pipeline strength, pipeline maturity, company strength and therapeutic area. The analysis aims to provide the necessary inputs to the stakeholders, enabling them to make the right decisions to conduct research work with the help the appropriate partner entities.

Chapter 11 features a comprehensive market forecast, highlighting the future potential of CRISPR-based genome editing services market till 2030. The projected opportunity has been further analyzed to develop a better perspective related to its distribution across [A] type of services (gRNA construction, cell line engineering and animal model generation), [B] type of cell line (mammalian, microbial, insect and others) and [C] different global regions (North America, Europe, Asia-Pacific and rest of the world).

Chapter 12 provides a discussion on important industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis, that highlights the relative impact of each SWOT parameter on the overall CRISPR-based genome editing services market. 

Chapter 13 is a collection of transcripts of the interviews conducted with representatives from renowned organizations that are engaged in the CRISPR technology domain. 

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 15 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Tables of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Context and Background
3.2. Overview of Genome Editing
3.3. History of Genome Editing
3.4. Applications of Genome Editing
3.5. Genome Editing Techniques
 
3.5.1. Mutagenesis
3.5.2 Conventional Homologous Recombination
3.5.3 Single Stranded Oligo DNA Nucleotides Homologous Recombination
3.5.4. Homing Endonuclease Systems (Adeno Associated Virus System)
 
3.5.5. Protein-based Nuclease Systems
3.5.5.1. Meganucleases
3.5.5.2. Zinc Finger Nucleases
3.5.5.3. Transcription Activator-like Effector Nucleases
 
3.5.6. DNA Guided Systems
3.5.6.1. Peptide Nucleic Acids
3.5.6.2. Triplex Forming Oligonucleotides
3.5.6.3. Structure Guided Endonucleases
 
3.5.7. RNA Guided Systems
3.5.7.1. CRISPR-Cas9
3.5.7.2. Targetrons
 
3.6. CRISPR-based Genome Editing
3.6.1. Role of CRISPR-Cas in Adaptive Immunity in Bacteria
3.6.2. Key CRISPR-Cas Systems
3.6.3. Components of CRISPR-Cas System
3.6.4. Protocol for CRISPR-based Genome Editing
 
3.7. Applications of CRISPR
3.7.1. Development of Therapeutic Interventions
3.7.2. Augmentation of Artificial Fertilization Techniques
3.7.3. Development of Genetically Modified Organisms
3.7.4. Production of Biofuels
3.7.5. Other Bioengineering Applications
 
3.8. Key Challenges and Future Perspectives
 
4. CRISPR-BASED GENOME EDITING SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. CRISPR-based Genome Editing Service Providers: Overall Market Landscape
4.2.3. Analysis by Type of Service Offering
4.2.4. Analysis by Type of gRNA Format
4.2.5. Analysis by Type of Endonuclease
4.2.6. Analysis by Type of Cas9 Format
4.2.7. Analysis by Type of Cell Line Engineering Offering
4.2.8. Analysis by Type of Animal Model Generation Offering
4.2.9. Analysis by Availability of CRISPR Libraries
4.2.10. Analysis by Year of Establishment
4.2.11. Analysis by Company Size
4.2.12. Analysis by Geographical Location
4.2.13. Logo Landscape: Distribution by Company Size and Location of Headquarters
 
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Parameters
5.4. CRISPR-based Genome Editing Service Providers: Competitive Landscape
5.4.1. Small-sized Companies
5.4.2. Mid-sized Companies
5.4.3. Large Companies
 
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Applied StemCell
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Recent Developments and Future Outlook
 
6.3. BioCat
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Recent Developments and Future Outlook
 
6.4. Biotools
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Recent Developments and Future Outlook
 
6.5. Charles River Laboratories
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Service Portfolio
6.5.4. Recent Developments and Future Outlook
 
6.6. Cobo Scientific
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Recent Developments and Future Outlook
 
6.7. Creative Biogene
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Recent Developments and Future Outlook
 
6.8. Cyagen Biosciences
6.8.1. Company Overview
6.8.2. Service Portfolio
6.8.3. Recent Developments and Future Outlook
 
6.9. GeneCopoeia
6.9.1. Company Overview
6.9.2. Service Portfolio
6.9.3. Recent Developments and Future Outlook
 
6.10. Horizon Discovery
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Service Portfolio
6.10.4. Recent Developments and Future Outlook
 
6.11. NemaMetrix
6.11.1. Company Overview
6.11.2. Service Portfolio
6.11.3. Recent Developments and Future Outlook
 
6.12. Synbio Technologies
6.12.1. Company Overview
6.12.2. Service Portfolio
6.12.3. Recent Developments and Future Outlook
 
6.13. Thermo Fisher Scientific
6.13.1. Company Overview
6.13.2. Financial Information
6.13.3. Service Portfolio
6.13.4. Recent Developments and Future Outlook
 
7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
 
7.3. CRISPR-based Genome Editing: Patent Analysis
7.3.1. Analysis by Application Year and Publication Year
7.3.2. Analysis by Geography
7.3.3. Analysis by CPC Symbols
7.3.4. Emerging Focus Areas
7.3.5. Leading Players: Analysis by Number of Patents
 
7.4. CRISPR-based Genome Editing: Patent Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics
7.5. Patent Valuation Analysis
 
8. ACADEMIC GRANT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Grants Awarded by the National Institutes of Health for CRISPR-based
8.3.1. Year-wise Trend of Grant Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Administering Institutes
8.3.4. Analysis by Support Period
8.3.5. Analysis by Funding Mechanism
8.3.6. Analysis by Type of Grant Application
8.3.7. Analysis by Grant Activity
8.3.8. Analysis by Recipient Organization
8.3.9. Regional Distribution of Grant Recipient Organization
8.3.10. Prominent Project Leaders: Analysis by Number of Grants
8.3.11. Emerging Focus Areas
8.3.12. Grant Attractiveness Analysis
 
9. CASE STUDY: ADVANCED CRISPR-BASED TECHNOLOGIES / SYSTEMS AND TOOLS
9.1. Chapter Overview
9.2. CRISPR-based Technology Providers
9.2.1. Analysis by Year of Establishment and Company Size
9.2.2. Analysis by Geographical Location and Company Expertise
9.2.3. Analysis by Focus Area
9.2.4. Key Technology Providers: Company Snapshots
9.2.4.1. APSIS Therapeutics
9.2.4.2. Beam Therapeutics
9.2.4.3. CRISPR Therapeutics
9.2.4.4. Editas Medicine
9.2.4.5. Intellia Therapeutics
9.2.4.6. Jenthera Therapeutics
9.2.4.7. KSQ Therapeutics
9.2.4.8. Locus Biosciences
9.2.4.9. Refuge Biotechnologies
9.2.4.10. Repare Therapeutics
9.2.4.11. SNIPR BIOME
9.2.5. Key Technology Providers: Summary of Venture Capital Investments
9.3. List of CRISPR Kit Providers
9.4. List of CRISPR Design Tool Providers
 
10. POTENTIAL STRATEGIC PARTNERS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Potential Strategic Partners for Genome Editing Service Providers
10.3.1. Key Industry Partners
10.3.1.1. Most Likely Partners
10.3.1.2. Likely Partners
10.3.1.3. Less Likely Partners
 
10.3.2. Key Non-Industry / Academic Partners
10.3.2.1. Most Likely Partners
10.3.2.2. Likely Partners
10.3.2.3. Less Likely Partners
 
11. MARKET FORECAST
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Overall CRISPR-based Genome Editing Services Market, 2019-2030
11.4. CRISPR-based Genome Editing Services Market: Distribution by Regions, 2019-2030
11.4.1. CRISPR-based Genome Editing Services Market in North America, 2019-2030
11.4.2. CRISPR-based Genome Editing Services Market in Europe, 2019-2030
11.4.3. CRISPR-based Genome Editing Services Market in Asia Pacific, 2019-2030
11.4.4. CRISPR-based Genome Editing Services Market in Rest of the World, 2019-2030
 
11.5. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, 2019-2030
11.5.1. CRISPR-based Genome Editing Services Market for gRNA Construction, 2019-2030
11.5.1.1. CRISPR-based Genome Editing Services Market for gRNA Construction in North America, 2019-2030
11.5.1.2. CRISPR-based Genome Editing Services Market for gRNA Construction in Europe, 2019-2030
11.5.1.3. CRISPR-based Genome Editing Services Market for gRNA Construction in Asia Pacific, 2019-2030
11.5.1.4. CRISPR-based Genome Editing Services Market for gRNA Construction in Rest of the World, 2019-2030
 
11.6.1. CRISPR-based Genome Editing Services Market for Cell Line Engineering, 2019-2030
11.6.1.1. CRISPR-based Genome Editing Services Market for Cell Line Engineering in North America, 2019-2030
11.6.1.2. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Europe, 2019-2030
11.6.1.3. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Asia Pacific, 2019-2030
11.6.1.4. 
 
11.7.1. CRISPR-based Genome Editing Services Market for Animal Model Generation, 2019-2030
11.7.1.1. CRISPR-based Genome Editing Services Market for Animal Model Generation in North America, 2019-2030
11.7.1.2. CRISPR-based Genome Editing Services Market for Animal Model Generation in Europe, 2019-2030
11.7.1.3. CRISPR-based Genome Editing Services Market for Animal Model Generation in Asia Pacific, 2019-2030
11.7.1.4. CRISPR-based Genome Editing Services Market for Animal Model Generation in Rest of the World, 2019-2030
 
11.8. CRISPR-based Genome Editing Services Market: Distribution by Type of Cell Line, 2019-2030
11.8.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines, 2019-2030
11.8.1.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in North America, 2019-2030
11.8.1.2. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Europe, 2019-2030
11.8.1.3. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Asia Pacific, 2019-2030
11.8.1.4. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Rest of the World, 2019-2030
 
11.9.1. CRISPR-based Genome Editing Services Market for Microbial Cell Lines, 2019-2030
11.9.1.1. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in North America, 2019-2030
11.9.1.2. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Europe, 2019-2030
11.9.1.3. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Asia Pacific, 2019-2030
11.9.1.4. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Rest of the World, 2019-2030
 
11.10.1. CRISPR-based Genome Editing Services Market for Other Cell Lines, 2019-2030
11.10.1.1. CRISPR-based Genome Editing Services Market for Other Cell Lines in North America, 2019-2030
11.10.1.2. CRISPR-based Genome Editing Services Market for Other Cell Lines in Europe, 2019-2030
11.10.1.3. CRISPR-based Genome Editing Services Market for Other Cell Lines in Asia Pacific, 2019-2030
11.10.1.4. CRISPR-based Genome Editing Services Market for Other Cell Lines in Rest of the World, 2019-2030
 
12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. SWOT Analysis
12.2.1. Strengths
12.2.2. Weaknesses
12.2.3. Opportunities
12.2.4. Threats
12.2.5. Concluding Remarks
 
13. EXECUTIVE INSIGHTS
 
14. APPENDIX 1: TABULATED DATA
 
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1. Genome Editing: Historical Milestones
Figure 3.2. Genome Editing Techniques
Figure 3.3. CRISPR-based Genome Editing Protocol
Figure 4.1. CRISPR-based Genome Editing Services: Distribution by Type of Service Offering
Figure 4.2. CRISPR-based Genome Editing Services: Distribution by Type of gRNA Format
Figure 4.3. CRISPR-based Genome Editing Services: Distribution by Type of Endonuclease
Figure 4.4. CRISPR-based Genome Editing Services: Distribution by Type of Cas9 Endonuclease Format
Figure 4.5. CRISPR-based Genome Editing Services: Distribution by Type of Cell Line Engineering
Figure 4.6. CRISPR-based Genome Editing Services: Distribution by Type of Animal Model Generation
Figure 4.7. CRISPR-based Genome Editing Services: Distribution by Availability of CRISPR Libraries
Figure 4.8. CRISPR-based Genome Editing Service Providers: Distribution by Year of Establishment
Figure 4.9. CRISPR-based Genome Editing Service Providers: Distribution by Company Size
Figure 4.10. CRISPR-based Genome Editing Service Providers: Distribution by Geographical Location
Figure 4.11. CRISPR-based Genome Editing Service Providers Logo Landscape: Distribution by Company Size and Location of Headquarters
Figure 5.1. Company Competitiveness Analysis: Assumptions and Key Parameters
Figure 5.2. Company Competitiveness Analysis: Small-sized Players
Figure 5.3. Company Competitiveness Analysis: Mid-sized Players
Figure 5.4. Company Competitiveness Analysis: Large Players
Figure 6.1. Charles River Laboratories: Annual Revenues, 2014–H1 2019 (USD Billion)
Figure 6.2. Horizon Discovery: Annual Revenues, 2014-H1 2019 (EUR Million)
Figure 6.3. Thermo Fisher Scientific: Annual Revenues, 2014-H1 2019 (USD Million)
Figure 7.1. Patent Portfolio: Distribution by Type of Patent
Figure 7.2. Patent Portfolio: Distribution by Application Year
Figure 7.3. Patent Portfolio: Distribution by Publication Year
Figure 7.4. Patent Portfolio: Distribution by Geography
Figure 7.5. Patent Portfolio: Distribution by CPC Symbols
Figure 7.6. Patent Portfolio: Emerging Focus Areas
Figure 7.7. Leading Industry Players: Distribution by Size of Patent Portfolio
Figure 7.8. Leading Non-Industry Players: Distribution by Size of Patent Portfolio
Figure 7.9. Patent Portfolio: Benchmarking by Patent Characteristics
Figure 7.10. Patent Portfolio: Valuation Analysis
Figure 8.1. Academic Grant Analysis: Year-wise Trend of Award
Figure 8.2. Academic Grant Analysis: Distribution by Amount Awarded
Figure 8.3. Academic Grant Analysis: Distribution by Administering Institutes
Figure 8.4. Academic Grant Analysis: Distribution by Support Period
Figure 8.5. Academic Grant Analysis: Distribution by Funding Mechanism
Figure 8.6. Academic Grant Analysis: Distribution by Type of Grant Application
Figure 8.7. Academic Grant Analysis: Distribution by Grant Activity
Figure 8.8. Academic Grant Analysis: Distribution by Recipient Organization
Figure 8.9. Academic Grant Analysis: Regional Distribution of Recipient Organization
Figure 8.10. Prominent Project Leaders: Distribution by Number of Grants Awarded
Figure 8.11. Academic Grant Analysis: Emerging Focus Areas
Figure 8.12. Academic Grant Analysis: Grant Attractiveness Analysis
Figure 9.1. CRISPR-based Technology Providers: Distribution by Year of Establishment
Figure 9.2. CRISPR-based Technology Providers: Distribution by Company Size
Figure 9.3. CRISPR-based Technology Providers: Distribution by Geographical Location and Company Expertise
Figure 9.4. CRISPR-based Technology Providers: Distribution by Focus Area
Figure 9.5. Key CRISPR-based Technology Providers: Venture Capital Investments (USD Million)
Figure 11.1. Overall CRISPR-based Genome Editing Services Market, 2019-2030 (USD Million)
Figure 11.2. CRISPR-based Genome Editing Services Market: Distribution by Regions, 2019-2030 (USD Million)
Figure 11.3. CRISPR-based Genome Editing Services Market in North America, 2019-2030 (USD Million)
Figure 11.4. CRISPR-based Genome Editing Services Market in Europe, 2019-2030 (USD Million)
Figure 11.5. CRISPR-based Genome Editing Services Market in Asia Pacific, 2019-2030 (USD Million)
Figure 11.6. CRISPR-based Genome Editing Services Market in Rest of the World, 2019-2030 (USD Million)
Figure 11.7. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, 2019-2030 (USD Million)
Figure 11.8. CRISPR-based Genome Editing Services Market for gRNA Construction, 2019-2030 (USD Million)
Figure 11.9. CRISPR-based Genome Editing Services Market for gRNA Construction in North America, 2019-2030 (USD Million)
Figure 11.10. CRISPR-based Genome Editing Services Market for gRNA Construction in
Figure 11.11. CRISPR-based Genome Editing Services Market for gRNA Construction in Asia Pacific, 2019-2030 (USD Million)
Figure 11.12. CRISPR-based Genome Editing Services Market for gRNA Construction in Rest of the World, 2019-2030 (USD Million)
Figure 11.13. CRISPR-based Genome Editing Services Market for Cell Line Engineering, 2019-2030 (USD Million)
Figure 11.14. CRISPR-based Genome Editing Services Market for Cell Line Engineering in North America, 2019-2030 (USD Million)
Figure 11.15. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Europe, 2019-2030 (USD Million)
Figure 11.16. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Asia Pacific, 2019-2030 (USD Million)
Figure 11.17. CRISPR-based Genome Editing Services Market for Cell Line Engineering in Rest of the World, 2019-2030 (USD Million)
Figure 11.18. CRISPR-based Genome Editing Services Market for Animal Model Generation, 2019-2030 (USD Million)
Figure 11.19. CRISPR-based Genome Editing Services Market for Animal Model Generation in North America, 2019-2030 (USD Million)
Figure 11.20. CRISPR-based Genome Editing Services Market for Animal Model Generation in Europe, 2019-2030 (USD Million)
Figure 11.21. CRISPR-based Genome Editing Services Market for Animal Model Generation in Asia Pacific, 2019-2030 (USD Million)
Figure 11.22. CRISPR-based Genome Editing Services Market for Animal Model Generation in Rest of the World, 2019-2030 (USD Million)
Figure 11.23. CRISPR-based Genome Editing Services Market: Distribution by Type of Cell Line, 2019-2030 (USD Million)
Figure 11.24. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines, 2019-2030 (USD Million)
Figure 11.25. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in North America, 2019-2030 (USD Million)
Figure 11.26. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Europe, 2019-2030 (USD Million)
Figure 11.27. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Asia Pacific, 2019-2030 (USD Million)
Figure 11.28. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines in Rest of the World, 2019-2030 (USD Million)
Figure 11.29. CRISPR-based Genome Editing Services Market for Microbial Cell Lines, 2019-2030 (USD Million)
Figure 11.30. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in North America, 2019-2030 (USD Million)
Figure 11.31. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Europe, 2019-2030 (USD Million)
Figure 11.32. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Asia Pacific, 2019-2030 (USD Million)
Figure 11.33. CRISPR-based Genome Editing Services Market for Microbial Cell Lines in Rest of the World, 2019-2030 (USD Million)
Figure 11.34. CRISPR-based Genome Editing Services Market for Other Cell Lines, 2019-2030 (USD Million)
Figure 11.35. CRISPR-based Genome Editing Services Market for Other Cell Lines in North America, 2019-2030 (USD Million)
Figure 11.36. CRISPR-based Genome Editing Services Market for Other Cell Lines in Europe, 2019-2030 (USD Million)
Figure 11.37. CRISPR-based Genome Editing Services Market for Other Cell Lines in Asia Pacific, 2019-2030 (USD Million)
Figure 11.38. CRISPR-based Genome Editing Services Market for Other Cell Lines in Rest of the World, 2019-2030 (USD Million)
Figure 12.1. CRISPR-based Genome Editing: SWOT Factors
Figure 12.2. Comparison of SWOT Factors: Harvey Ball Analysis

List of Tables

Table 3.1. Classification of CRISPR-Cas Systems
Table 4.1. List of CRISPR-based Genome Editing Service Providers: Information on Type of Service
Table 4.2. List of CRISPR-based Genome Editing Service Providers: Information on gRNA Format, Type of Endonuclease and Cas9 Endonuclease Format
Table 4.3. List of CRISPR-based Genome Editing Service Providers: Information on Cell Line Engineering Offerings, Animal Model Generation Offerings and Availability of CRISPR Libraries
Table 5.1. Company Competitive Analysis: Small-sized Players
Table 5.2. Company Competitive Analysis: Mid-sized Players
Table 5.3. Company Competitive Analysis: Large Players
Table 6.1. CRISPR-based Genome Editing Services Providers: List of Companies Profiled
Table 6.2. Applied StemCell: Company Overview
Table 6.3. Applied StemCell: CRISPR-based Genome Editing Services
Table 6.4. Applied StemCell: Recent Developments and Future Outlook
Table 6.5. BioCat: Company Overview
Table 6.6. BioCat: CRISPR-based Genome Editing Services
Table 6.7. BioCat: Recent Developments and Future Outlook
Table 6.8. Charles River Laboratories: Company Overview
Table 6.9. Charles River Laboratories: CRISPR-based Genome Editing Services
Table 6.10. Charles River Laboratories: Recent Developments and Future Outlook
Table 6.11. Cobo Scientific: Company Overview
Table 6.12. Cobo Scientific: CRISPR-based Genome Editing Services
Table 6.13. Cobo Scientific: Recent Developments and Future Outlook
Table 6.14. Creative Biogene: Company Overview
Table 6.15. Creative Biogene: CRISPR-based Genome Editing Services
Table 6.16. Creative Biogene: Recent Developments and Future Outlook
Table 6.17. Cyagen Biosciences: Company Overview
Table 6.18. Cyagen Biosciences: CRISPR-based Genome Editing Services
Table 6.19. Cyagen Biosciences: Recent Developments and Future Outlook
Table 6.20. GeneCopoeia: Company Overview
Table 6.21. GeneCopoeia: CRISPR-based Genome Editing Services
Table 6.22. GeneCopoeia: Recent Developments and Future Outlook
Table 6.23. Horizon Discovery: Company Overview
Table 6.24. Horizon Discovery: CRISPR-based Genome Editing Services
Table 6.25. Horizon Discovery: Recent Developments and Future Outlook
Table 6.26. NemaMetrix: Company Overview
Table 6.27. NemaMetrix: CRISPR-based Genome Editing Services
Table 6.28. NemaMetrix: Recent Developments and Future Outlook
Table 6.29. Synbio Technologies: Company Overview
Table 6.30. Synbio Technologies: CRISPR-based Genome Editing Services
Table 6.31. Synbio Technologies: Recent Developments and Future Outlook
Table 6.32. Thermo Fisher Scientific: Company Overview
Table 6.33. Thermo Fisher Scientific: CRISPR-based Genome Editing Services
Table 6.34. Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 8.1. Grant Analysis: List of Most Attractive Grants
Table 9.1. List of CRISPR-based Technology Providers
Table 9.2. List of CRISPR-based Technology Providers: Information on Technology
Table 9.3. Beam Therapeutics: Funding Instances
Table 9.4. Beam Therapeutics: Collaborations
Table 9.5. CRISPR Therapeutics: Funding Instances
Table 9.6. CRISPR Therapeutics: Collaborations
Table 9.7. Editas Medicine: Funding Instances
Table 9.8. Editas Medicine: Collaborations
Table 9.9. KSQ Therapeutics: Funding Instances
Table 9.10. Locus Biosciences: Funding Instances
Table 9.11. Locus Biosciences: Collaborations
Table 9.12. Refuge Biotechnologies: Funding Instances
Table 9.13. Refuge Biotechnologies: Collaborations
Table 9.14. Repare Therapeutics: Funding Instances
Table 9.15. SNIPR BIOME: Funding Instances
Table 9.16. Intellia Therapeutics: Funding Instances
Table 9.17. Intellia Therapeutics: Collaborations
Table 9.18. List of CRISPR Kit Providers
Table 9.19. List of CRISPR Design Tool Providers
Table 10.1. Industry Players: Most Likely Partners
Table 10.2. Industry Players: Likely Partners
Table 10.3. Industry Players: Less Likely Partners
Table 10.4. Non-Industry Players: Most Likely Partners
Table 10.5. Non-Industry Players: Likely Partners
Table 10.6. Non-Industry Players: Less Likely Partners
Table 14.1. CRISPR-based Genome Editing Services: Distribution by Type of Service Offering
Table 14.2. CRISPR-based Genome Editing Services: Distribution by Type of gRNA Format
Table 14.3. CRISPR-based Genome Editing Services: Distribution by Type of Endonuclease
Table 14.4. CRISPR-based Genome Editing Services: Distribution by Type of Cas9 Endonuclease Format
Table 14.5. CRISPR-based Genome Editing Services: Distribution by Type of Cell Line Engineering
Table 14.6. CRISPR-based Genome Editing Services: Distribution by Type of Animal Model Generation
Table 14.7. CRISPR-based Genome Editing Services: Distribution by Availability of CRISPR Libraries
Table 14.8. CRISPR-based Genome Editing Service Providers: Distribution by Year of Establishment
Table 14.9. CRISPR-based Genome Editing Service Providers: Distribution by Company Size
Table 14.10. CRISPR-based Genome Editing Service Providers: Distribution by Geographical Location
Table 14.11. CRISPR-based Genome Editing Service Providers Logo Landscape: Distribution by Company Size and Location of Headquarters
Table 14.12. Charles River Laboratories: Annual Revenues, 2014–H1 2019 (USD Billion)
Table 14.13. Horizon Discovery: Annual Revenues, 2014-H1 2019 (EUR Million)
Table 14.14. Thermo Fisher Scientific: Annual Revenues, 2014-H1 2019 (USD Million)
Table 14.15. Patent Portfolio: Distribution by Type of Patent
Table 14.16. Patent Portfolio: Distribution by Application Year
Table 14.17. Patent Portfolio: Distribution by Publication Year
Table 14.18. Patent Portfolio: Distribution by Geography
Table 14.19. Leading Industry Players: Distribution by Size of Patent Portfolio
Table 14.20. Leading Non-Industry Players: Distribution by Size of Patent Portfolio
Table 14.21. Patent Portfolio: Valuation Analysis
Table 14.22. Academic Grant Analysis: Year-wise Trend of Award
Table 14.23. Academic Grant Analysis: Distribution by Amount Awarded
Table 14.24. Academic Grant Analysis: Distribution by Administering Institutes
Table 14.25. Academic Grant Analysis: Distribution by Support Period
Table 14.26. Academic Grant Analysis: Distribution by Funding Mechanism
Table 14.27. Academic Grant Analysis: Distribution by Type of Grant Application
Table 14.28. Academic Grant Analysis: Distribution by Grant Activity
Table 14.29. Academic Grant Analysis: Distribution by Recipient Organization
Table 14.30. Prominent Project Leaders: Distribution by Number of Grants Awarded
Table 14.31. Academic Grant Analysis: Grant Attractiveness Analysis
Table 14.32. CRISPR-based Technology Providers: Distribution by Year of Establishment
Table 14.33. CRISPR-based Technology Providers: Distribution by Company Size
Table 14.34. CRISPR-based Technology Providers: Distribution by Focus Area
Table 14.35. Key CRISPR-based Technology Providers: Venture Capital Investments (USD Million)
Table 14.36. Overall CRISPR-based Genome Editing Services Market, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.37. CRISPR-based Genome Editing Services Market: Distribution by Regions, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.38. CRISPR-based Genome Editing Services Market in North America, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.39. CRISPR-based Genome Editing Services Market in Europe, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.40. CRISPR-based Genome Editing Services Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.41. CRISPR-based Genome Editing Services Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.42. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.43. CRISPR-based Genome Editing Services Market for gRNA Construction, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.44. CRISPR-based Genome Editing Services Market for gRNA Construction in North America, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.45. CRISPR-based Genome Editing Services Market for gRNA Construction in Europe, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.46. CRISPR-based Genome Editing Services Market for gRNA Construction in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.47. CRISPR-based Genome Editing Services Market for gRNA Construction in Rest of the World, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.48. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.49. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.50. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.51. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.52. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.53. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.54. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.55. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.56. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.57. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.58. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.59. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.60. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.61. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.62. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.63. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.64. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.65. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.66. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.67. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.68. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.69. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.70. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.71. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.72. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.73. CRISPR-based Genome Editing Services Market for Cell Line Engineering, Conservative, Base and Optimistic Scenarios, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)

List of Companies

  1. 302 Military Hospital of China
  2. 4D Molecular Therapeutics
  3. AAVogen
  4. AB SCIEX 
  5. AbbVie
  6. AbCheck
  7. AbClon
  8. Abeona Therapeutics 
  9. ACROBiosystems
  10. Actus Therapeutics
  11. Acucela
  12. Adaptimmune Therapeutics
  13. Adicet Bio
  14. Advantagene
  15. Advaxis
  16. Adverum Biotechnologies
  17. Adverum Biotechnologies
  18. Aeon Therapeutics
  19. Affiliated Hospital to Academy of Military Medical Sciences
  20. Agency for Science, Technology and Research (A*STAR)
  21. AgenTus Therapeutics
  22. Agilent Technologies
  23. Agilis Biotherapeutics
  24. Akouos
  25. Albert Einstein College of Medicine
  26. Aldevron
  27. Alex's Lemonade Stand Foundation
  28. Allergan
  29. Allife Medical Science and Technology
  30. Allogene Therapeutics
  31. AlphaVax
  32. ALSTEM
  33. Altor Bioscience
  34. American Gene Technologies
  35. Amgen
  36. Amicus Therapeutics
  37. AMS Biotechnology
  38. Anaeropharma Science
  39. Analytical Biological Services
  40. Anchiano Therapeutics
  41. AnGes
  42. Angionetics
  43. Anhui Provincial Hospital
  44. Animalab
  45. Antagene
  46. Antibody Design Labs
  47. Apic Bio
  48. Applied Biological Materials (abm)
  49. Applied Genetic Technologies (AGTC)
  50. Applied StemCell
  51. APSIS Therapeutics
  52. ARBELE
  53. Arbor Biosciences
  54. Arthrogen
  55. Aruvant Sciences
  56. AskBio
  57. Astellas Pharma
  58. Atara Biotherapeutics
  59. Atossa Genetics
  60. Atreca
  61. ATUM
  62. Auburn University
  63. Audentes Therapeutics
  64. AuraGen
  65. Aurora Biopharma
  66. Autolus
  67. Avacta
  68. Avectas
  69. AveXis
  70. AVROBIO
  71. Axol Bioscience
  72. Axovant Gene Therapies
  73. Bamboo Therapeutics
  74. Baxter
  75. Bayer
  76. Baylor College of Medicine
  77. Beam Therapeutics
  78. Beijing Biohealthcare Biotechnology
  79. Beijing Cancer Hospital
  80. Beijing Doing Biomedical
  81. Beijing Immunochina Medical Science & Technology
  82. Beijing Lu Daopei Hospital
  83. Beijing Mario Biotech
  84. Beijing Sanbo Brain Hospital
  85. Beijing Sanwater Biological Technology
  86. Bellicum Pharmaceuticals
  87. Benchling
  88. Berlin Institute of Health
  89. Bill & Melinda Gates Foundation
  90. BioAtla
  91. BioCat
  92. Bioceltech Therapeutics
  93. BioChain
  94. Biocodon Technologies
  95. Biocytogen
  96. Biogen
  97. BioInvent
  98. Biolegio
  99. Biologics International
  100. BioMarin
  101. Bioneer
  102. Bionic Sight
  103. BioNTech
  104. Biotools
  105. Bioverativ
  106. Blue Heron Biotech
  107. bluebird bio
  108. B-MoGen Biotechnologies
  109. Boehringer Ingelheim
  110. Boston Children's Hospital
  111. Bristol-Myers Squibb
  112. Broad Institute 
  113. Brown University
  114. Butterfly sciences
  115. California Institute for Regenerative Medicine
  116. California Institute of Technology
  117. Calimmune
  118. Cambridge Bioscience
  119. Cancer Research UK
  120. Canopy BioSciences
  121. Captain T Cell
  122. Cardiogen Sciences
  123. Caribou Biosciences
  124. Carina Biotech
  125. CARsgen Therapeutics
  126. Cartesian Therapeutics
  127. Cartherics
  128. Case Comprehensive Cancer Center
  129. CASPR Biotech
  130. Castle Creek Pharma
  131. Celenex
  132. Celgene
  133. Cell and Gene Therapy Catapult
  134. Cell Medica
  135. Cellecta
  136. Cellectis
  137. CellGenTech
  138. CellSystems
  139. Cellular Biomedicine Group
  140. Cellular Therapeutics
  141. Celsion
  142. Celvab
  143. Celyad
  144. Center for Applied Medical Research (CIMA)
  145. Center for Cell and Gene Therapy
  146. Changhai Hospital
  147. Changzheng Hospital
  148. Charles River Laboratories
  149. Chatham Therapeutics
  150. Chiba University
  151. Children's Hospital and Health System Foundation
  152. Children's Hospital of Fudan University
  153. Children's Hospital of Philadelphia
  154. Children's Mercy Kansas City
  155. China Immunotech
  156. China Meitan General Hospital
  157. Chinese Academy of Sciences
  158. Chinese PLA General Hospital
  159. City of Hope National Medical Center
  160. Cobo Scientific
  161. Coderegenesis 
  162. Cold Genesys
  163. CombiGene
  164. Copernicus Therapeutics
  165. Cosmo Bio
  166. Creative Bioarray
  167. Creative Biogene
  168. CRISPR Therapeutics
  169. CrownBio
  170. CSL Behring
  171. Cyagen
  172. Cynvec
  173. Cytovant Sciences
  174. Daiichi Sankyo
  175. Dana-Farber Cancer Institute
  176. Defense Advanced Research Projects Agency (DARPA)
  177. DefiniGEN
  178. Desktop Genetics
  179. Dimension Therapeutics
  180. Discovery Genomics
  181. DNAlite Therapeutics
  182. DNAtrix
  183. Dongguan People's Hospital
  184. Dow AgroSciences
  185. Duke University Medical Center
  186. Duke-NUS Medical School
  187. EdiGene
  188. Editas Medicine
  189. eGenesis Bio
  190. Ehime University
  191. Eli Lilly
  192. Endocyte
  193. Endsulin
  194. Enochian BioSciences
  195. Entos Pharmaceuticals
  196. Epeius Biotechnologies
  197. Errant Gene Therapeutics
  198. ERS Genomics
  199. Esteve
  200. Eureka Therapeutics
  201. Eutilex
  202. Exonics Therapeutics
  203. ExpressCells
  204. Expression Therapeutics
  205. EXUMA Biotechnology
  206. Eyevensys
  207. F1 Oncology
  208. Fate Therapeutics
  209. Federal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology
  210. Fibrocell
  211. First Affiliated Hospital of Chengdu Medical College
  212. First Affiliated Hospital of Guangdong Pharmaceutical University
  213. First Affiliated Hospital of Zhejiang University
  214. First People's Hospital of Foshan
  215. First People's Hospital of Yunnan
  216. FIT Biotech
  217. Five Prime Therapeutics
  218. FKD Therapies
  219. Flexion Therapeutics
  220. Fondazione Matilde Tettamanti Menotti De Marchi Onlus
  221. Forevertek Biotechnology
  222. Formula Pharmaceuticals
  223. Fosun Pharma
  224. Fred Hutchinson Cancer Research Center
  225. Freeline Therapeutics
  226. Fuda Cancer Hospital
  227. Fudan University
  228. Fujian Cancer Hospital
  229. Fujian Medical University
  230. Fujita Health University
  231. Fulcrum Therapeutics 
  232. Gadeta
  233. GEG Tech
  234. Gemini Therapeutics
  235. Genable Technologies
  236. GenAhead Bio
  237. GeneCopoeia
  238. GeneCure Biotechnologies
  239. GenEdit
  240. Genelux
  241. Genentech
  242. GeneOne Life Science
  243. GenePharma
  244. GeneQuine Biotherapeutics
  245. Generation Bio
  246. Genethon
  247. Genetics Research
  248. GENEWIZ 
  249. Genexine 
  250. Genmab
  251. genOway
  252. Genprex
  253. GenScript
  254. GenSight Biologics
  255. Genus Oncology
  256. GenVec
  257. German Cancer Research Center
  258. GigaGen
  259. GlaxoSmithKline
  260. Glycostem
  261. Gracell Biotechnologies
  262. Gradalis
  263. Green Cross Cell
  264. GSK
  265. Guangdong General Hospital
  266. Guangdong Xiangxue Precision Medical Technology
  267. Guangdong Zhaotai InVivo Biomedicine
  268. Guangzhou Anjie Biomedical Technology
  269. Guangzhou Doublle Bioproducts
  270. Guangzhou Eighth People's Hospital
  271. Guangzhou FineImmune Biotechnology
  272. Guangzhou First People's Hospital
  273. Guangzhou Yi Yan Biological Technology
  274. Gynecologic Oncology Group Foundation
  275. Gyroscope Therapeutics
  276. Hanyang University
  277. Harvard College
  278. Harvard University
  279. Hebei Senlang Biotechnology
  280. Hebei Yanda Ludaopei Hospital
  281. Hefei Binhu Hospital
  282. Heidelberg University
  283. Helix BioPharma
  284. Helixmith 
  285. Hemera Biosciences
  286. Henan Cancer Hospital
  287. Henan Hualong Biotechnology
  288. Herantis Pharma
  289. Histogenics
  290. Holostem Terapie Avanzate
  291. Homology Medicines
  292. HORAMA
  293. Horizon Discovery
  294. Hrain Biotechnology
  295. Huaian First People's Hospital
  296. Huazhong Agricultural University
  297. Huazhong University of Science and Technology
  298. Human Stem Cells Institute 
  299. Hunan Provincial People's Hospital
  300. Hunan Yongren Medical Innovation
  301. Hunan Zhaotai Yongren Biotech
  302. Hunterian Medicine 
  303. Icahn School of Medicine at Mount Sinai
  304. iCAR Bio Therapeutics
  305. iCarTAB BioMed
  306. iCell Gene Therapeutics
  307. Icell Kealex Therapeutics
  308. ICON
  309. IDeal Genetics
  310. i-DNA Biotechnology
  311. ILPEN Scientific Equipment & Supplies
  312. Immatics
  313. Immune Therapeutics
  314. Immunocore
  315. ImmunoGenes
  316. Immusoft
  317. ingenious targeting laboratory
  318. Innovative Cellular Therapeutics
  319. Inotek Pharmaceuticals
  320. Inovio Pharmaceuticals
  321. Inscripta
  322. Institute of Hematology & Blood Diseases Hospital
  323. Integrated DNA Technologies 
  324. Intellia Therapeutics
  325. Intrexon
  326. Invectys
  327. Iowa State University
  328. IVERIC bio
  329. IWK Health Centre is affiliated to Dalhousie University, to be added as separate entries 
  330. Janssen Pharmaceuticals
  331. Jennerex Biotherapeutics
  332. Jenthera Therapeutics
  333. Jichi Medical University
  334. Jingzhou Central Hospital
  335. Johns Hopkins Kimmel Cancer Center
  336. Jonsson Comprehensive Cancer Center
  337. Juno Therapeutics
  338. Juventas Therapeutics
  339. JW Biotechnology
  340. KAEDI
  341. King's College London
  342. Kite Pharma
  343. Kolon TissueGene
  344. Krystal Biotech
  345. KSQ Therapeutics
  346. Labomics
  347. Lacerta Therapeutics
  348. Leiden University Medical Center
  349. Leland Stanford Junior University 
  350. Leucid Bio
  351. LifeEDIT
  352. Ligandal
  353. Liminatus Pharma
  354. Lion TCR
  355. Living Pharma
  356. Locus Biosciences
  357. LogicBio Therapeutics
  358. Lokon Pharma
  359. Lonza
  360. Loop Genomics
  361. Loyola University
  362. LubioScience
  363. Lucigen
  364. Ludwig Cancer Research
  365. Lysogene
  366. MabVax Therapeutics
  367. Macrogen
  368. Mammoth Biosciences
  369. Marino Biotechnology
  370. Marsala Biotech
  371. Massachusetts General Hospital
  372. Massachusetts Institute of Technology
  373. MaxCyte
  374. Mayo Clinic
  375. MD Anderson Cancer Center
  376. Medical College of Wisconsin
  377. Medigene
  378. MedImmune
  379. Medisix Therapeutics
  380. MeiraGTx
  381. Memorial Sloan Kettering Cancer Center
  382. Merck
  383. Mesoblast
  384. Microsynth
  385. Mie University Hospital
  386. Milo Biotechnology
  387. Miltenyi Biotec
  388. Minerva Biotechnologies
  389. MingJu Therapeutics
  390. Mirimus
  391. Moffitt Cancer Center
  392. MolMed
  393. Momotaro-Gene
  394. Monsanto
  395. MultiVir
  396. Mustang Bio
  397. Myonexus Therapeutics
  398. Nagoya University
  399. Nanfang Hospital of Southern Medical University
  400. Nanjing Children's Hospital
  401. Nanjing Legend Biotech
  402. NanoCor Therapeutics
  403. Nanogenics
  404. Nanosens Innovations
  405. National Cancer Institute
  406. National Eye Institute
  407. National Heart, Lung, and Blood Institute
  408. National Human Genome Research Institute 
  409. National Institute of Aging
  410. National Institute of Allergy and Infectious Diseases
  411. National Institute of Arthritis and Musculoskeletal and Skin Diseases
  412. National Institute of Child Health and Human Development
  413. National Institute of Diabetes and Digestive and Kidney Diseases
  414. National Institute of General Medical Sciences
  415. National Institute of Mental Health
  416. National Institute of Neurological Disorders and Stroke
  417. National Institute on Drug Abuse
  418. National Institutes of Health
  419. Nationwide Children's Hospital
  420. Navy General Hospital
  421. Ncardia
  422. NemaMetrix
  423. Neuracle Genetics
  424. Neuralgene
  425. Neurocrine Biosciences
  426. Neurogene
  427. New England Biolabs
  428. Nightstar Therapeutics
  429. Ningbo Cancer Hospital
  430. NIPRO
  431. NMI TT Pharmaservices
  432. Noahgen
  433. Nohla Therapeutics
  434. Noile-Immune Biotech
  435. Novartis
  436. NTrans Technologies
  437. Obsidian Therapeutics
  438. Ocugen
  439. omicX
  440. Oncolys BioPharma
  441. Oncos Therapeutics
  442. OncoSec Medical
  443. Orbit Biomedical
  444. ORCA Therapeutics
  445. Orchard Therapeutics
  446. OriGene Technologies
  447. Ottawa Hospital Research Institute
  448. Oxford BioMedica
  449. Oxford Genetics
  450. OZ Biosciences
  451. Pacific Biosciences
  452. Parker Institute for Cancer Immunotherapy
  453. Passage Bio
  454. Pattern BioSciences
  455. Peking University
  456. PeproMene Bio
  457. PeriphaGen
  458. PersonGen BioTherapeutics
  459. Peter MacCallum Cancer Centre
  460. Pfizer
  461. PHENOMIN-ICS
  462. Pinze Lifetechnology
  463. Pioneer Hi-Bred International
  464. PlasmaTech Biopharmaceuticals
  465. PNA Bio
  466. PolyGene
  467. Poseida Therapeutics
  468. Precigen
  469. Precision BioSciences
  470. Precision Genome Engineering
  471. Precision Virologics
  472. Prevail Therapeutics
  473. Promab Biotechnologies
  474. Promega
  475. Promethera Biosciences
  476. Protheragen
  477. PsiOxus Therapeutics
  478. PTC Therapeutics
  479. Purdue University
  480. Qingdao Central Hospital
  481. Quethera 
  482. Recombinetics
  483. Refuge Biotechnologies
  484. Regeneron Pharmaceuticals
  485. REGENXBIO
  486. RenJi Hospital
  487. Renova Therapeutics
  488. Rentschler Biopharma
  489. Repare Therapeutics
  490. ReproCELL
  491. RetroSense Therapeutics
  492. Reyon Pharmaceutical
  493. Roche
  494. Rocket Pharmaceuticals
  495. Rockland Immunochemicals
  496. Roger Williams Medical Center
  497. Roswell Park Cancer Institute
  498. Royal Adelaide Hospital Cancer Centre
  499. Ruijin Hospital
  500. Ryboquin
  501. San Raffaele Hospital
  502. Sanct
  503. Sangamo Therapeutics
  504. Sanofi
  505. Sarepta Therapeutics
  506. SCANBUR
  507. Scancell
  508. SciGenom Labs
  509. Scotia Biologics
  510. Seattle Children's Hospital
  511. Seattle Children's Research Institute
  512. Seattle Genetics
  513. Second Affiliated Hospital of Guangzhou Medical University
  514. Second Affiliated Hospital of Xi'an Jiaotong University
  515. Second Military Medical University
  516. Second Xiangya Hospital of Central South University
  517. Selecta Biosciences
  518. Servier
  519. Shanghai Bioray Laboratory
  520. Shanghai Changzheng Hospital
  521. Shanghai Children's Medical Center
  522. Shanghai East Hospital
  523. Shanghai GeneChem
  524. Shanghai General Hospital
  525. Shanghai International Medical Center
  526. Shanghai Jiao Tong University School of Medicine
  527. Shanghai Longyao Biotechnology
  528. Shanghai Public Health Clinical Center
  529. Shanghai Sinobioway Sunterra Biotech
  530. Shanghai Sixth People's Hospital
  531. Shanghai Sunway Biotech
  532. Shanghai Tenth People's Hospital
  533. Shanghai Tong Ren Hospital
  534. Shanghai Tongji Hospital
  535. Shanghai Unicar-Therapy Bio-medicine Technology
  536. Sheba Medical Center
  537. Shenzhen BinDeBio
  538. Shenzhen Geno-immune Medical Institute
  539. Shenzhen Institute for Innovation and Translational Medicine
  540. Shenzhen Second People's Hospital
  541. Sherlock Biosciences
  542. Shionogi
  543. Shire (acquired by Takeda Pharmaceutical)
  544. Sibiono GeneTech
  545. Sichuan University
  546. Sidney Kimmel Cancer Center
  547. Sigma Aldrich
  548. SillaJen
  549. Sinobioway Cell Therapy
  550. SNIPR BIOME
  551. Solid Biosciences
  552. Sorrento Therapeutics
  553. Southern Medical University
  554. Southwest Hospital
  555. Spanish National Centre for Biotechnology
  556. Spark Therapeutics
  557. Spindle Biotech
  558. SR-TIGET
  559. St. Jude Children's Research Hospital
  560. Stanford University
  561. STEMCELL Technologies
  562. Stony Brook University
  563. StrideBio
  564. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  565. SunyBiotech
  566. Super-T Cell Cancer Company
  567. Syd Labs
  568. Symvivo
  569. Synbio Technologies
  570. Syngenta Participations
  571. Synthego
  572. System Biosciences
  573. Taconic Biosciences
  574. Tactiva Therapeutics
  575. Takara Bio
  576. Takeda Pharmaceutical
  577. Targazyme
  578. Targovax
  579. Tasly Biopharmaceuticals
  580. Taxus Cardium Pharmaceuticals
  581. TC BioPharm
  582. TCR2 Therapeutics
  583. TCRCure Biopharma
  584. tebu-bio
  585. Tenaya Therapeutics
  586. Tessa Therapeutics
  587. Texas Children's Hospital
  588. The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
  589. The Bambino Gesu` Children's Hospital
  590. The Beijing Pregene Science and Technology
  591. The Cancer Hospital of Yunnan
  592. The First Affiliated Hospital of Anhui Medical University
  593. The First Affiliated Hospital of Chongqing Medical University
  594. The First Affiliated Hospital of Harbin Medical University
  595. The First Affiliated Hospital of Jinan University
  596. The First Affiliated Hospital of Soochow University
  597. The First Affiliated Hospital of Wenzhou Medical University
  598. The First Affiliated Hospital of Zhengzhou University
  599. The First Affiliated Hospital with Nanjing Medical University
  600. The First Hospital of Jilin University
  601. The First People's Hospital of Hefei
  602. The First People's Hospital of Yuhang District
  603. The General Hospital of Western Theater Command
  604. The Methodist Hospital System
  605. The Netherlands Cancer Institute
  606. The Pregene (ShenZhen) Biotechnology
  607. The Second Affiliated Hospital of Hainan Medical University
  608. The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
  609. The Second Hospital of Anhui Medical University
  610. The Second Hospital of Hebei Medical University
  611. The Second Hospital of Nanjing Medical University
  612. The Second Military Medical University
  613. The Sixth Affiliated Hospital of Wenzhou Medical University
  614. The Third Affiliated Hospital of Southern Medical University
  615. The University of Chicago
  616. The Wistar Institute
  617. TheraBiologics
  618. THERAVECTYS
  619. Thermo Fisher Scientific
  620. Third Affiliated Hospital
  621. Third Military Medical University
  622. Thomas Jefferson University
  623. THP Medical Products
  624. Tianjin Medical University Cancer Institute and Hospital
  625. Tianjin Mycure Medical Technology
  626. Tianjin People's Hospital
  627. TILT Therapeutics
  628. Timmune Biotech
  629. Tmunity Therapeutics
  630. TNK Therapeutics, subsidiary of Sorrento Therapeutics
  631. Tocagen
  632. Tongji Hospital
  633. Tongji Medical College
  634. Tongji University School of Medicine
  635. Toni Stephenson Lymphoma Center
  636. ToolGen
  637. Transgene
  638. Transposagen Biopharmaceuticals
  639. Trilink Biotechnologies
  640. TxCell
  641. UC Davis Medical Center
  642. UK Cystic Fibrosis Gene Therapy Consortium
  643. Ultragenyx Pharmaceutical
  644. UNC Lineberger Comprehensive Cancer Center
  645. Union Stem Cell & Gene Engineering
  646. uniQure Biopharma
  647. United States Department of Defense
  648. Universal Cells
  649. Universitat Autònoma de Barcelona
  650. University Health Network
  651. University Hospital Heidelberg
  652. University Medical Center Utrecht
  653. University of Bergen
  654. University of California
  655. University of Cologne
  656. University of Connecticut
  657. University of Florida
  658. University of Georgia 
  659. University of Massachusetts Medical School
  660. University of Oxford
  661. University of Pennsylvania
  662. University of Southern California
  663. University of Technology
  664. University of Texas MD Anderson Cancer Center
  665. University of Zurich
  666. Unum Therapeutics
  667. Uppsala University
  668. Urovant Sciences
  669. UT Southwestern Medical Center
  670. V Foundation
  671. ValueAct Capital Management
  672. VBL Therapeutics
  673. VCN Biosciences
  674. Vector Neurosciences
  675. VectorBuilder
  676. Velaz
  677. Vertex Pharmaceuticals
  678. Verve Therapeutics
  679. Vessl™
  680. Vigene Biosciences
  681. Virttu Biologics
  682. Vivet Therapeutics
  683. Vivo Bio Tech
  684. Vor Biopharma
  685. Voyager Therapeutics
  686. Washington University
  687. Weill Cornell Medical College
  688. Welgen
  689. West China Hospital
  690. Wuhan Sian Medical Technology
  691. Wuhan Union Hospital
  692. WuXi AppTec
  693. Wyvern Pharmaceuticals
  694. Xiangxue Life Sciences
  695. Xiangxue Pharmaceutical
  696. Xiangyang Central Hospital
  697. Xijing Hospital
  698. Xinqiao Hospital
  699. XpressBio
  700. Xuanwu Hospital
  701. Xuzhou Medical University
  702. XyloCor Therapeutics
  703. Yake Biotechnology
  704. Yale University
  705. Yamaguchi University Graduate School of Medicine
  706. Yan'an Affiliated Hospital of Kunming Medical University
  707. Yuanyi Biotechnology
  708. ZeClinics
  709. Zelluna Immunotherapy
  710. ZenBio
  711. Zhejiang University
  712. Zhongshan Hospital
  713. Zhujiang Hospital of Southern Medical University
  714. Ziopharm Oncology

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com